InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced that the first subject has been dosed in ...

SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of artificial intelligence (AI)-based solutions for skin is excited to announce the publication of a case study highlighting the use of ...

Aclaris Therapeutics has secured an exclusive license from Biosion for the global rights to two new antibodies.

ICP-332 is a potent and selective TYK2 inhibitor that is being developed for the treatment of various T-cell related autoimmune disorders, including atopic dermatitis (AD), vitiligo, inflammatory ...

ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitis ZORYVE, a next-generation topical phosphodiesterase-4 ...

In the last few months, Pfizer has won approvals in the EU and US for JAK inhibitor Cibinqo (abrocitinib) as a treatment for moderate-to-severe atopic dermatitis in adults who cannot get relief ...

The following is a summary of “Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic ...

Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...

The Digital Medicine Society (DiME) is today releasing a new set of open-access resources to advance the use of nocturnal scratch in the treatment of atopic dermatitis (AD). Night-time flare-ups ...

Eczema is relatively common, affecting 20 percent of children and 10 percent of adults around the world (1). If you are one of the many who experiences eczema, you know the symptoms, which can include ...

Organon is a strong investment opportunity with a high yield, diversified portfolio, steady performance, and transformative ...

The company's FDA-approved drug Sofdra is the first for the common and embarrassing condition of excessive sweating.